PE20120361A1 - Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico - Google Patents

Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico

Info

Publication number
PE20120361A1
PE20120361A1 PE2011002129A PE2011002129A PE20120361A1 PE 20120361 A1 PE20120361 A1 PE 20120361A1 PE 2011002129 A PE2011002129 A PE 2011002129A PE 2011002129 A PE2011002129 A PE 2011002129A PE 20120361 A1 PE20120361 A1 PE 20120361A1
Authority
PE
Peru
Prior art keywords
hydroximethyl
metoxy
fluorobenzyl
methylpropyl
oxo
Prior art date
Application number
PE2011002129A
Other languages
English (en)
Spanish (es)
Inventor
Motohide Satoh
Takahisa Motomura
Takashi Matsuda
Kentaro Kondo
Koji Ando
Koji Matsuda
Shuji Miyake
Hideto Uehara
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20120361A1 publication Critical patent/PE20120361A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2011002129A 2004-05-20 2005-05-20 Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico PE20120361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20

Publications (1)

Publication Number Publication Date
PE20120361A1 true PE20120361A1 (es) 2012-05-03

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011002129A PE20120361A1 (es) 2004-05-20 2005-05-20 Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico
PE2005000561A PE20060358A1 (es) 2004-05-20 2005-05-20 Cristal estable del compuesto 4-oxoquinolina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2005000561A PE20060358A1 (es) 2004-05-20 2005-05-20 Cristal estable del compuesto 4-oxoquinolina

Country Status (33)

Country Link
US (7) US7635704B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP4299563A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3754064B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20080064909A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1956961B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR049280A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2005245296B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2024C511I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0510114B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2566922C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (4) CY1113010T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1636190T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2960824T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI3281939T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR23C1040I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20120681T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE064615T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL179250A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT3281939T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00334I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA06013405A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY134672A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (8) NO339223B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ551839A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (2) PE20120361A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL3281939T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1636190E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS64845B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2330845C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1636190T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI329015B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2005113508A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200610647B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
EP2272516A3 (en) * 2002-11-20 2011-03-16 Japan Tobacco, Inc. 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
KR20140082858A (ko) 2005-12-30 2014-07-02 길리애드 사이언시즈, 인코포레이티드 Hiv 인테그라제 억제제의 약동학을 개선하기 위한 방법
EP2452682A1 (en) 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
IN2014CN00613A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2006-03-06 2015-08-21 Japan Tobacco Inc
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
US7939553B2 (en) 2006-07-07 2011-05-10 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008033836A2 (en) 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
PT2118082E (pt) * 2007-02-23 2014-12-12 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de terapêuticas
KR20100040892A (ko) * 2007-06-29 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
EP2167089A1 (en) * 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
CA2720856C (en) 2008-05-02 2016-02-02 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
MX2011008289A (es) 2009-02-06 2011-09-15 Gilead Sciences Inc Tabletas para terapia combinada.
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
RU2015103913A (ru) 2012-07-06 2016-08-27 Дженентек, Инк. N-замещенные бензамиды и способы их применение
EA026089B1 (ru) 2012-08-03 2017-02-28 Джилид Сайэнс, Инк. Способ и промежуточные соединения для получения ингибиторов интегразы
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
CN111303152B (zh) 2012-12-21 2023-04-11 吉利德科学公司 多环-氨基甲酰基吡啶酮化合物及其药物用途
NO2865735T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-07-12 2018-07-21
ES2645192T3 (es) 2013-07-12 2017-12-04 Gilead Sciences, Inc. Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
HK1249103B (en) 2015-04-02 2020-02-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2,4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1970-09-14 1981-02-16
JPS4826772A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd 8−ジフルオロメトキシキノリン−3−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd 7−フェニルピペラジニルキノリン−3−カルボン酸誘導体
HUT76643A (en) * 1994-07-18 1997-10-28 Sankyo Co Trifluoromethylquinolinecarboxylic acid derivative, pharmaceutical compositions containing them and their use
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
US6187775B1 (en) 1996-04-12 2001-02-13 The United States Of America As Represented By The Department Of Health And Human Services Acridone-derived compounds useful as antineoplastic and antiretroviral agents
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Icam−1産生阻害剤
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248736B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE60124577T2 (de) 2000-10-12 2007-09-27 Merck & Co., Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
CA2425067A1 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
ATE411292T1 (de) 2001-03-01 2008-10-15 Shionogi & Co Stickstoffhaltige heteroarylverbindungen mit hiv- integrase inhibierender wirkung
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用
EP2272516A3 (en) * 2002-11-20 2011-03-16 Japan Tobacco, Inc. 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy

Also Published As

Publication number Publication date
PE20060358A1 (es) 2006-05-12
NO347902B1 (no) 2024-05-06
AU2005245296B2 (en) 2010-08-12
TW200600097A (en) 2006-01-01
MY134672A (en) 2007-12-31
BRPI0510114A (pt) 2007-09-25
HUS2400006I1 (hu) 2024-04-28
CY2015009I2 (el) 2024-09-20
HUE064615T2 (hu) 2024-04-28
EP2514746A1 (en) 2012-10-24
US7635704B2 (en) 2009-12-22
AR096100A2 (es) 2015-12-09
RS52375B (en) 2012-12-31
CY2015009I1 (el) 2024-09-20
ZA200610647B (en) 2008-06-25
NO20200873A1 (no) 2007-02-07
US20180029989A1 (en) 2018-02-01
CY2024008I1 (el) 2024-09-20
HK1083341A1 (en) 2006-06-30
NO20230913A1 (no) 2007-02-07
IL179250A0 (en) 2007-03-08
BRPI0510114B8 (pt) 2021-05-25
PT1636190E (pt) 2012-08-20
US20150361044A1 (en) 2015-12-17
EP4299563A3 (en) 2024-02-28
FI3281939T3 (fi) 2023-10-23
FIC20240008I1 (fi) 2024-03-20
HRP20231588T3 (hr) 2024-03-15
WO2005113508A1 (en) 2005-12-01
BE2024C511I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2024-10-08
FR23C1040I1 (fr) 2023-12-29
US20250091995A1 (en) 2025-03-20
AU2005245296A1 (en) 2005-12-01
CN1956961A (zh) 2007-05-02
US20060030710A1 (en) 2006-02-09
EP1636190B1 (en) 2012-06-27
PL1636190T3 (pl) 2012-10-31
MXPA06013405A (es) 2007-03-01
SI1636190T1 (sl) 2012-09-28
EP3281939B1 (en) 2023-10-18
NO20065790L (no) 2007-02-07
CA2566922C (en) 2011-01-11
US20220235009A1 (en) 2022-07-28
CY2024008I2 (el) 2024-09-20
NO339223B1 (no) 2016-11-21
EP3281939A1 (en) 2018-02-14
ES2960824T3 (es) 2024-03-06
PT3281939T (pt) 2023-11-22
NZ551839A (en) 2009-11-27
US8981103B2 (en) 2015-03-17
SI3281939T1 (sl) 2024-02-29
JP3754064B2 (ja) 2006-03-08
PL3281939T3 (pl) 2024-03-18
RU2330845C1 (ru) 2008-08-10
AR049280A1 (es) 2006-07-12
JP2006001927A (ja) 2006-01-05
LUC00334I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2024-07-01
CY1113010T1 (el) 2016-04-13
NO20190051A1 (no) 2007-02-07
TWI329015B (en) 2010-08-21
DK1636190T3 (da) 2012-09-24
EP4299563A2 (en) 2024-01-03
EP1636190A1 (en) 2006-03-22
NO20161297A1 (no) 2007-02-07
CN1956961B (zh) 2010-05-26
NO20220690A1 (no) 2007-02-07
CA2566922A1 (en) 2005-12-01
US20190185433A1 (en) 2019-06-20
LT3281939T (lt) 2023-11-27
DK3281939T3 (da) 2024-01-22
KR20080064909A (ko) 2008-07-09
US20100204271A1 (en) 2010-08-12
BRPI0510114B1 (pt) 2020-09-15
RS64845B1 (sr) 2023-12-29
NO2024034I1 (no) 2024-07-15
NO20240384A1 (no) 2007-02-07
CY1126560T1 (el) 2024-09-20
HRP20120681T1 (hr) 2012-09-30
ES2388441T3 (es) 2012-10-15

Similar Documents

Publication Publication Date Title
PE20120361A1 (es) Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
WO2009055006A8 (en) Deuterated darunavir
MY146669A (en) Pyrazole derivatives for treating hiv
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
MX2010005292A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
UA41265C2 (uk) Кристалічна форма (-)-цис-4-аміно-1-(2-гідроксиметил-1,3-оксатіолан-5-іл)-(1н)-піримідин-2-ону (варіанти), способи її отримання та фармацевтична композиція
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
UA100005C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY33479A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
RU2009120992A (ru) Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции
AR030021A1 (es) COMPUESTO DE UNA PIRIMIDINONAS SUSTITUIDA,COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y EL USO DE DICHO COMPUESTO Y DE DICHA COMPOSICIoN EN LA FABRICACIoN DE MEDICAMENTOS uTILES PARA LA INHIBICION SELECTIVA DE LA CASCADA DE COAGULACIoN
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
BRPI0519013A2 (pt) composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
GB0113524D0 (en) Pyrazole derivatives
CY1113279T1 (el) Φαρμακευτικη συνθεση 271
NO20052520D0 (no) Nye sulfamider

Legal Events

Date Code Title Description
FG Grant, registration